keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine breast cancer

keyword
https://www.readbyqxmd.com/read/28106244/second-malignancy-risk-in-patients-with-bronchopulmonary-carcinoids-epidemiological-results-from-italian-network-of-cancer-registries
#1
Filippo Lococo, Carla Galeone, Claudio Sacchettini, Giovanni Leuzzi, Alfredo Cesario, Massimiliano Paci, Lucia Mangone
PURPOSE: This epidemiological study aimed to determine the prevalence and characteristics of second tumors (STs) in patients with bronchopulmonary carcinoids (BCs). METHODS: Data on neuroendocrine carcinomas (NECs) from the AIRTUM registry (1975-2011) were used for the analysis. Among 32,325 NECs, we focused our analysis on 3,205 patients (9.9%) affected by BCs. The overall ST number and incidence were calculated. The number of STs was compared with the expected cancer number in the healthy Italian population, and the standardized incidence ratio (SIR) and 95% confidence intervals were calculated...
January 16, 2017: Tumori
https://www.readbyqxmd.com/read/28098562/primary-neuroendocrine-carcinoma-of-the-breast-a-single-center-experience-and-review-of-the-literature
#2
Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni
: Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification...
December 6, 2016: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/28068959/pancreatic-neuroendocrine-tumor-with-metastasis-to-the-spleen-a-case-report
#3
Yasunaru Sakuma, Yoshikazu Yasuda, Naohiro Sata, Yoshinori Hosoya, Atsushi Shimizu, Hirofumi Fujii, Daisuke Matsubara, Noriyuki Fukushima, Atsushi Miki, Misato Maeno, Alan Kawarai Lefor
BACKGROUND: Long-term term survival in patients with pancreatic neuroendocrine tumors has been reported, even in patients with metastatic disease. Metastases to the spleen are extremely rare, but have been reported from a number of primary malignancies, such as breast cancer, lung cancer, melanoma and ovarian cancer. This is the first report of a splenic metastasis from a primary pancreatic neuroendocrine tumor. CASE PRESENTATION: The patient presented as a 53 years old white male with anemia and fatigue...
January 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/27980106/imatinib-spares-ckit-expressing-prostate-neuroendocrine-tumors-whereas-kills-seminal-vesicle-epithelial-stromal-tumors-targeting-pdgfr-%C3%AE
#4
Elena Jachetti, Alice Rigoni, Lucia Bongiovanni, Ivano Arioli, Laura Botti, Mariella Parenza, Valeria Cancila, Claudia Chiodoni, Fabrizio Festinese, Matteo Bellone, Regina Tardanico, Claudio Tripodo, Mario P Colombo
Prostate cancer is a leading cause of death by cancer in male worldwide. Indeed, advanced and metastatic disease characterized by androgen resistance and often associated with neuroendocrine (NE) differentiation remains incurable. Using the spontaneous prostate cancer TRAMP model, we have shown that mast cells (MCs) support in vivo the growth of prostate adenocarcinoma, whereas their genetic or pharmacologic targeting favours prostate NE cancer arousal. Aiming at simultaneously targeting prostate NE tumor cells and MCs, both expressing the cKit tyrosine kinase receptor, we have tested the therapeutic effect of Imatinib in TRAMP mice...
December 15, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27925203/the-genetic-landscape-of-breast-carcinomas-with-neuroendocrine-differentiation
#5
Caterina Marchiò, Felipe C Geyer, Charlotte Ky Ng, Salvatore Piscuoglio, Maria R De Filippo, Marco Cupo, Anne M Schultheis, Raymond S Lim, Kathleen A Burke, Elena Guerini-Rocco, Mauro Papotti, Larry Norton, Anna Sapino, Britta Weigelt, Jorge S Reis-Filho
Neuroendocrine breast carcinomas (NBCs) account for 2-5% of all invasive breast cancers, and are histologically similar to neuroendocrine tumours from other sites. They typically express oestrogen receptor (ER), and are HER2-negative and of luminal 'intrinsic' subtype. Here, we sought to define the mutational profile of NBCs, and to investigate whether NBCs and common forms of luminal (ER(+) /HER2(-) ) breast carcinoma show distinct repertoires of somatic mutations. Eighteen ER(+) /HER2(-) NBCs, defined as harbouring >50% of tumour cells expressing chromogranin A and/or synaptophysin, and matched normal tissues were microdissected and subjected to massively parallel sequencing targeting all exons of 254 genes most frequently mutated in breast carcinomas and/or related to DNA repair...
December 7, 2016: Journal of Pathology
https://www.readbyqxmd.com/read/27915478/targeting-the-phosphatidylinositol-3-kinase-pathway-in-gastric-cancer-can-omics-improve-outcomes
#6
REVIEW
Phu Tran, Cham Nguyen, Samuel J Klempner
Phosphatidylinositol-3-kinase (PI3K) pathway signaling is an established oncogenic signal transduction pathway implicated in multiple malignancies. Therapeutic targeting of PI3K pathway components has improved outcomes in chronic lymphocytic leukemia, kidney cancer, breast cancer, and neuroendocrine tumors. Gastric cancers harbor some of the highest rates of oncogenic alterations in PI3K but attempts to translate this genomic observation have met with limited clinical success and novel approaches are needed...
November 2016: International Neurourology Journal
https://www.readbyqxmd.com/read/27905324/primary-neuroendocrine-carcinoma-of-the-breast-a-single-center-experience-and-review-of-the-literature
#7
Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni
: Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification...
November 28, 2016: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/27879489/breast-fibroadenoma-with-increased-activity-on-68ga-dotatate-pet-ct
#8
Georgios Z Papadakis, Corina Millo, Samira M Sadowski, Apostolos H Karantanas, Ulas Bagci, Nicholas J Patronas
Fibroadenoma is the most common benign breast tumor in women of reproductive age, carrying little to no risk of breast cancer development. We report on a case of a woman with history of neuroendocrine tumor who on follow-up imaging tests underwent whole-body PET/CT study using Ga DOTATATE. The scan showed increased focal activity in the right breast, which was biopsied revealing a fibroadenoma. The presented data suggests cell surface overexpression of somatostatin receptors by this benign breast tumor. Moreover, this finding emphasizes the need for cautious interpretation of Ga DOTATATE-avid breast lesions that could mimic malignancy in neuroendocrine tumor patients...
February 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27870680/liver-metastases-from-noncolorectal-malignancies-neuroendocrine-tumor-sarcoma-melanoma-breast
#9
Erica S Alexander, Michael C Soulen
Patients with noncolorectal hepatic metastases often face limited treatment options and a dismal prognosis. Over the last decade, the advent of targeted immunotherapies has transformed the treatment of certain metastatic cancers, such as sarcoma and melanoma; however, these patients eventually develop resistance. Metastatic sarcoma, melanoma, and breast and neuroendocrine tumors are notoriously treatment resistant once they have metastasized to the liver. For these cancers, minimally invasive transarterial and ablation therapies have emerged as safe, palliative therapies that can provide symptom control and even prolong survival...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27858925/-dermatomyositis-as-the-first-manifestation-of-small-cell-carcinoma-case-report-and-literature-review
#10
Herman Ahumada Piña, Luis Fuentes Cabrera, Rodrigo Selamé Glena, Daniel García Oneto, Andrea Jiménez Aguilar, Claudia Durán Herrera, Jorge Ávila Pérez, Maximiliano Cortés Latorre
Dermatomyositis is an autoimmune inflammatory myopathy associated with dermatologic findings. Its association with neoplasms is widely reported and has been shown to be higher in lung cancer, particularly small-cell carcinoma, probably as it originates from neuroendocrine cell precursors, as well as breast and ovarian cancer. The low frequency of dermatomyositis makes it difficult to suspect the underlying lesions among the diagnostic possibilities of systemic diseases with cutaneous manifestations. Therefore, the high probability of a neoplasm should always be considered, with reports of up to 75% in the eastern population and about 40% in general...
November 15, 2016: Medwave
https://www.readbyqxmd.com/read/27835867/keratin-13-expression-reprograms-bone-and-brain-metastases-of-human-prostate-cancer-cells
#11
Qinlong Li, Lijuan Yin, Lawrence W Jones, Gina C-Y Chu, Jason B-Y Wu, Jen-Ming Huang, Quanlin Li, Sungyong You, Jayoung Kim, Yi-Tsung Lu, Stefan Mrdenovic, Ruoxiang Wang, Michael R Freeman, Isla Garraway, Michael S Lewis, Leland W K Chung, Haiyen E Zhau
Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients...
November 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27802189/a-case-of-multicentric-low-grade-neuroendocrine-breast-tumor-with-an-unusual-histological-pattern
#12
Antonio D'Antonio, Maria Addesso, Domenico Memoli, Annamaria Cascone, Luigi Cremone
Neuroendocrine features are detectable in carcinomas of the breast either as scattered cells, that are recognized by their expression of neuroendocrine cell markers. Instead, pure breast carcinomas with neuroendocrine features (NEBC) are very rare and represent <1% of all breast cancer. Usually NEBC may be well or poorly differentiated and more frequent in older woman. These tumors showed variable histological pattern but a common feature is represented by expression of neuroendocrine markers. Here we report a case of a primary multicentric low-grade neuroendocrine carcinoma of the breast presented because of its rarity and for the unusual tubular and cribriform pattern resembling a well-differentiated conventional breast carcinoma...
October 14, 2016: Breast Disease
https://www.readbyqxmd.com/read/27793528/-mucinous-carcinoma-of-the-breast-clinical-biological-and-evolutive-profile
#13
N Naqos, A Naim, H Jouhadi, A Taleb, Z Bouchbika, N Benchakroune, N Tawfiq, S Sahraoui, A Benider
PURPOSE: Mucinous carcinoma of the breast accounts for 1 to 4% of all breast cancer. There are two histological subtypes: mixed mucinous carcinoma, where the ductal carcinoma is associated with the colloid component, and pure mucinous carcinoma, with a favorable prognosis, where the mucus surrounds the tumour tissue and constitutes a mechanical barrier limiting cell invasion and making this form less aggressive. Our study aimed to determine retrospectively the main epidemiological, clinical, biological, and therapeutic features, as well as the prognosis of this rare form of breast carcinoma...
December 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/27750238/us-us-fusion-imaging-in-radiofrequency-ablation-for-liver-metastases
#14
Yasunori Minami, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Tadaaki Arizumi, Masahiro Takita, Norihisa Yada, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Naoshi Nishida, Masatoshi Kudo
OBJECTIVE: Radiofrequency ablation (RFA) induces gas bubbles in ablation zones, and the ablative margin cannot be evaluated accurately on ultrasound (US) during and immediately after RFA. This study assessed the usefulness of US-US fusion imaging to visualize the ablative margin of RFA for liver metastasis. METHODS: RFA guided by US-US fusion imaging was performed on 12 targeted tumors in 10 patients. Secondary hepatic malignancies included patients with colorectal cancer (n = 4), breast cancer (n = 2), lung cancer (n = 1), gastrointestinal stromal tumor (n = 1), pancreatic neuroendocrine tumor (n = 1), and adrenocortical carcinoma (n = 1)...
2016: Digestive Diseases
https://www.readbyqxmd.com/read/27712099/the-pathophysiologic-role-of-disrupted-circadian-and-neuroendocrine-rhythms-in-breast-carcinogenesis
#15
Lonnele J Ball, Oxana Palesh, Lance J Kriegsfeld
Most physiological processes in the brain and body exhibit daily (circadian) rhythms coordinated by an endogenous master clock located in the suprachiasmatic nucleus of the hypothalamus that are essential for normal health and functioning. Exposure to sunlight during the day and darkness at night optimally entrains biological rhythms to promote homeostasis and human health. Unfortunately, a major consequence of the modern lifestyle is increased exposure to sun-free environments during the day and artificial lighting at night...
October 2016: Endocrine Reviews
https://www.readbyqxmd.com/read/27661665/pancreatic-resection-for-renal-cell-carcinoma-metastasis-an-exceptionally-rare-coexistence
#16
Stergios Boussios, Ioannis Zerdes, Ourania Batsi, Vasilios P Papakostas, Esmeralda Seraj, George Pentheroudakis, George K Glantzounis
INTRODUCTION: Pancreatic metastases are uncommon and only found in a minority of patients with widespread metastatic disease at autopsy. The most common primary cancer site resulting in pancreatic metastases is the kidney, followed by colorectal cancer, melanoma, breast cancer, lung carcinoma and sarcoma. PRESENTATION OF CASE: Herein, we report a 63-year-old male patient who presented -3.5 years after radical nephrectomy performed for renal cell carcinoma (RCC)-with a well-defined lobular, round mass at the body of the pancreas demonstrated by abdominal Magnetic Resonance Imaging (MRI)...
2016: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/27638528/-new-prognostic-and-predictive-markers-for-breast-cancer
#17
D L Wachter
Breast cancer can be divided into four molecular subtypes with different prognoses using immunohistochemical markers in the routine clinicopathological work-up. The protein Ki-67 is of central importance in this context, in particular to distinguish between luminal A and luminal B carcinomas. Determination of the Ki-67 index of a carcinoma also allows a prediction of the likelihood of the response to chemotherapy. Additionally, the expression of certain cytokeratins in tumor cells is associated with a poor response to chemotherapy...
November 2016: Der Pathologe
https://www.readbyqxmd.com/read/27628324/mash1-is-highly-specific-for-neuroendocrine-carcinomas-an-immunohistochemical-evaluation-on-normal-and-various-neoplastic-tissues
#18
David Altree-Tacha, Jillian Tyrrell, Faqian Li
Context .- High-grade neuroendocrine carcinomas and carcinoids can arise in different sites such as lung, gastrointestinal tract, prostate, and skin. Classic neuroendocrine markers such as CD56, synaptophysin, and chromogranin cannot distinguish carcinoids from high-grade neuroendocrine carcinomas. Recently, mouse monoclonal mASH1 has been shown to help discriminate carcinoids from high-grade neuroendocrine carcinomas in various neoplastic sites. To date, there have been no comprehensive immunohistochemistry studies with mASH1 on nonneuroendocrine neoplasms...
September 15, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27561878/highly-increased-125i-jr11-antagonist-binding-in-vitro-reveals-novel-indications-for-sst2-targeting-in-human-cancers
#19
Jean Claude Reubi, Beatrice Waser, Helmut R Maecke, Jean E Rivier
: There is recent in vitro and in vivo evidence that somatostatin receptor sst2 antagonists are better tools to target neuroendocrine tumors (NET) than sst2 agonists. Indeed, antagonists bind to a greater number of sst2 sites than agonists. Whether sst2 antagonists could be used successfully to target non-NET tumors, expressing low sst2 density, is unknown. Here, we compare quantitatively (125)I-JR11 sst2 antagonist binding in vitro with that of the sst2 agonist (125)I-Tyr3-octreotide in large varieties of non-NET and NET...
August 25, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27529726/design-synthesis-and-evaluation-of-a-neurokinin-1-receptor-targeted-near-ir-dye-for-fluorescence-guided-surgery-of-neuroendocrine-cancers
#20
Ananda Kumar Kanduluru, Madduri Srinivasarao, Philip S Low
The neurokinin-1 receptor (NK1R) is implicated in the growth and metastasis of many tumors, including cancers of the brain (e.g., gliomas, glioblastomas, and astrocytomas), skin (e.g., melanomas), and neuroendocrine tissues (cancers of the breast, stomach, pancreas, larynx, and colon). Because overexpression of NK1R has been reported in most of these malignancies, we have undertaken designing an NK1R-targeted near-infrared (NIR) fluorescent dye for fluorescence-guided surgeries of these cancers. We demonstrate here that an NK1R-binding ligand linked to the NIR dye LS288 selectively accumulates in NK1R-expressing tumor xenografts with high affinity (Kd = 13 nM), allowing intraoperative imaging of these cancers in live mice...
September 21, 2016: Bioconjugate Chemistry
keyword
keyword
105241
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"